| P2093 | author name string | S Sprague | |
| | S Ott | |
| | W Goodman | |
| | K Martin | |
| | T Drüeke | |
| | K Olgaard | |
| | J Cunningham | |
| | N Lameire | |
| | G Eknoyan | |
| | S Moe | |
| P2860 | cites work | Fetuin-A and extraosseous calcification in uremia | Q28254226 |
| | Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee | Q29616160 |
| | Circulating biochemical markers of bone remodeling in uremic patients | Q33650293 |
| | Biological markers in the diagnosis of the different forms of renal osteodystrophy | Q34028875 |
| | The burden of kidney disease: improving global outcomes | Q34354600 |
| | Percutaneous bone biopsy in the diagnosis of renal osteodystrophy | Q34638558 |
| | Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy | Q35674615 |
| | Osteoporosis in chronic kidney disease. | Q35674619 |
| | Uremic vasculopathy | Q35921135 |
| | Calcification and cardiovascular problems in renal failure | Q36063984 |
| | Diagnostic and prognostic value of coronary artery calcium screening | Q36225436 |
| | Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia | Q36277026 |
| | Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. | Q38519191 |
| | Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients | Q44039636 |
| | Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). | Q46480414 |
| | Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density | Q46522344 |
| | Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. | Q50991761 |
| | Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. | Q53970602 |
| | Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. | Q64913104 |
| | The spectrum of bone disease in end-stage renal failure--an evolving disorder | Q70580279 |
| | Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure | Q73387179 |
| | New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study | Q73556145 |
| | Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease | Q74756562 |
| | A bridge to improving healthcare outcomes and quality of life | Q76380709 |
| | The evolution of assays for parathyroid hormone | Q80994757 |
| | Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry | Q81072140 |
| | With or without the kidney: the role of FGF23 in CKD | Q81666635 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal osteodystrophy | Q822598 |
| P304 | page(s) | 1945-53 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | |
| P478 | volume | 69 | |